Exact Sciences beats analysts' expectations for first quarter

Madison-based Exact Sciences reported a net loss of $10.9 million (17 cents/share) on revenues of $1 million for the first quarter ending March 31, which slightly beat analysts’ predictions of a 20 cents/share net loss. Still, the company’s stock fell 29 cents on news of the loss. A year ago, Exact Sciences reported a net loss of $10.6 million (19 cents/share) on revenues of $1 million. The company is developing non-invasive, stool-based tests for colorectal cancer.